pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

TAG: Depression

Jul 18, 2023

Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder

Mar 6, 2023

Denovo Biopharma Creates Innovative Gene Registry Program to Support the First Precision Medicine for Treatment Resistant Depression

Feb 28, 2023

Cessation Therapeutics’ Anti-Fentanyl Monoclonal Antibody Treatment Shows Promise in Protecting Against Fentanyl-Induced Overdose

Sep 8, 2022

Autobahn Therapeutics Announces Successful Financing to Support Strategic Advancement of ABX-002 for Treatment Resistant Depression

Aug 10, 2022

Psilera's New Compounds Show Potential for Significant Treatment Improvement in Depression and Neurodegenerative Disorders

May 17, 2022

Curebase, Flow Neuroscience Announce Joint Clinical Trial for the use of an at-home tDCS device for treating depression

Jan 31, 2022

Denovo Biopharma LLC Announces FDA Approval of IND to Initiate First Biomarker-Guided Global CNS Clinical Trial for Treatment-Resistant Depression (TRD)

Dec 16, 2021

Pear Therapeutics Announces the Acquisition of Two Assets Addressing a Comprehensive Spectrum of Depression Conditions

Nov 18, 2021

Bexson Biomedical Announces Expansion to Treat Major Depression with Wearable Ketamine Formulation

Jan 8, 2021

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Oct 29, 2020

Mebias Discovery Receives Grant from NIDA to Advance MEB-1170 as an Analgesic Drug Candidate for the Prevention and Treatment of Opioid Use Disorder

Mar 12, 2020

Denovo Biopharma Announces Breakthrough Discovery of a Novel Genetic Biomarker for DB104 (Liafensine) for Depression

Feb 10, 2020

NeuroRx: Phase 3 Drug for Suicidal Bipolar Depression to Present at BIO CEO Conference

Jan 8, 2020

NeuroRx Drug for Suicidal Bipolar Depression Receives Notification of Patent Allowance

Dec 11, 2019

BlackThorn Therapeutics Reports Data Supporting Phase 2 Development of KOR Antagonist, BTRX-335140, in Depression and Other CNS Disorders

Jul 18, 2019

Pear Therapeutics Announces FDA Submission for Somryst™, a Prescription Digital Therapeutic for the Treatment of Adults with Chronic Insomnia and Depression

Jul 9, 2019

NeuroRx Initiates Pivotal Study for NRX-101, a Breakthrough Designation Therapy Targeting Suicidal Bipolar Depression

May 30, 2019

NeuroRx Reports Phase 2 Efficacy for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

May 23, 2019

Cadent Therapeutics Receives Milestone Payment for Initiation of Phase 2 Trial of MIJ821 in Treatment-Resistant Depression

Jan 24, 2019

Navitor Pharmaceuticals Commences Phase 1 Clinical Evaluation of NV-5138, a Novel mTORC1 Activator in Patients with Treatment-Resistant Depression

Dec 13, 2018

NeuroRx Presents Phase 2 Efficacy & Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

Dec 13, 2018

NeuroRx Presents Phase 2 Efficacy and Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

Nov 13, 2018

NeuroRx Receives FDA Breakthrough Therapy Designation for NRX-101, First Oral Drug Targeting Suicidal Bipolar Depression

Sep 4, 2018

NeuroRx Announces Phase 2 Data from NRX-101, Initiates Pivotal Study for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB)

Jun 26, 2018

Navitor Pharmaceuticals Initiates a Clinical Study of NV-5138, a Novel, Oral Small Molecule for Treatment-Resistant Depression

Jun 11, 2018

NeuroRx, Inc. Completes Phase 2b/3 Feasibility Enrollment for First Glx-Targeted Oral Drug Targeting Suicidal Bipolar Depression

May 7, 2018

NeuroRx Receives Special Protocol Agreement (SPA) and Biomarker Letter of Support from FDA for Pivotal Studies of NRX-101 to treat Severe Bipolar Depression in Patients with Acute Suicidal Ideation & Behavior

May 7, 2018

NeuroRx Receives Special Protocol Agreement (SPA) and Biomarker Letter of Support from FDA for Pivotal Studies of NRX-101 to treat Severe Bipolar Depression in Patients with Acute Suicidal Ideation and Behavior

Dec 27, 2017

NeuroRx Signs Agreement With U.S. Dept. of Veterans Affairs and Baylor College of Medicine for Clinical Trial of First Drug Regimen Targeting Severe Bipolar Depression in Patients With Acute Suicidal Ideation & Behavior (ASIB)

Dec 27, 2017

NeuroRx Signs Agreement With U.S. Dept. of Veterans Affairs and Baylor College of Medicine for Clinical Trial of First Drug Regimen Targeting Severe Bipolar Depression in Patients With Acute Suicidal Ideation and Behavior (ASIB)

Sep 6, 2017

NeuroRx Awarded FDA Fast Track Designation for First Drug Regimen Targeting Suicide in Bipolar Depression

Aug 15, 2017

Magellan Health Continues to Develop Digital Therapies through Enhanced Collaboration with Click Therapeutics

Jan 5, 2017

Amorsa Therapeutics Announces Strategic Collaboration Facilitated by Johnson and Johnson Innovation to Develop New Therapy for Treatment-Resistant Depression

Oct 21, 2015

American Psychiatric Association Task Force Report Identifies Potential Value of NeuroRx Active Ingredient for Treatment of Depression

Jun 24, 2015

NeuroRx Announces First Human Trial Results Targeting Sustained Treatment of Bipolar Depression & Suicidality

Jun 24, 2015

NeuroRx Announces First Human Trial Results Targeting Sustained Treatment of Bipolar Depression and Suicidality